KYMR vs. SNY: Kymera Therapeutics vs. Sanofi Stock Comparison

Company Profile

Kymera Therapeutics (KYMR) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but KYMR is classified in Biotechnology while SNY is classified in Pharmaceuticals.

Sanofi (SNY) has more than two decades of public-market history since July 1, 2002, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Kymera Therapeutics (KYMR) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while Sanofi (SNY) is defensive at 0.28 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Sanofi (SNY) reports 5.72%, ranking against industry peers normally.

Sanofi (SNY) at 8.20% retains a top-quartile share of revenue as profit, ahead of Kymera Therapeutics (KYMR) at 0.00%, which keeps about the industry-typical share.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Sanofi (SNY) reports 30.89%, ranking against industry peers normally.

Profitability Metrics

Growth

Sanofi (SNY) at 5.49% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

Both Kymera Therapeutics (KYMR) at 0.05 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Kymera Therapeutics (KYMR) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Kymera Therapeutics (KYMR) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Sanofi (SNY) trades at 23.40 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Kymera Therapeutics (KYMR) at 110.00 prices above its industry range — a wide gap in sales valuation between them.

Sanofi (SNY) at 1.38 looks cheap against book in the lower P/B ratio quartile, while Kymera Therapeutics (KYMR) at 6.96 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics